English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

Platform Specialty Products sales up 191% in Q1 2015qrcode

May. 13, 2015

Favorites Print
Forward
May. 13, 2015
Net sales of Platform Specialty Products Corp.increased 191.1% to $534.8 million in the first quarter of 2015 versus the same period of last year. On a pro forma as adjusted basis net sales declined 6.7% from $666.7 million to $622.3 million, attributable primarily to foreign exchange headwinds. On a constant currency basis, pro forma as adjusted net sales were up 9.6% year-over-year.

The company’s Agricultural Solutions business recorded an 8.5% decrease in pro forma as adjusted sales from $483 million in the first quarter of 2014 to $442.0 million. On a constant currency basis, pro forma as adjusted sales grew 11.2% or $44.3 million.

The net loss increased to $26.3 million, compared to $5.9 million for the same period in 2014, as it struggled with currency exchange rates and a challenging agchem environment. On a pro forma as adjusted basis net income rose 12.8% from $41.2 million to $46.5 million and pro forma as adjusted net income attributable to common shareholders was also up 13.0% to $46.4 million.

Daniel H. Leever, Platform's Chief Executive Officer, commented, “We had a busy yet exciting start to 2015 as we completed the Arysta acquisition and rapidly began integrating our Agricultural Solutions businesses. Our efforts have already resulted in meaningful synergies, and our strategy to focus on specialty crops in niche sectors enabled us to outperform the sector this quarter. We believe our consolidated double-digit, constant currency growth and strong margin performance is a clear indicator of the momentum and strength we possess across our business lines. While currency remains a substantial headwind, we are actively working to mitigate these pressures. Our strong sales pipeline keeps us on track to meet our 2015 targets and we remain laser focused on driving cash flow generation.”

Frank J. Monteiro, Platform's Chief Financial Officer, added, “We are extremely pleased with our financial performance this quarter, especially in the context of a challenging agrochemical industry landscape and currency headwinds. The underlying health of our business is evident from our double-digit constant currency growth. Our strong operating performance is attributable to robust sales of our high margin products in the agrochemical business and healthy demand for products within our Electronic Solutions end market.”

Wayne Hewett, Platform's President, noted, “The steps we took this quarter to solidify our management infrastructure and bring together our agrochemicals businesses lay the foundation for our long-term growth and success. Our integration work proceeds steadily, and we believe we have direct line of sight to our targeted $80 million of synergies over the next three years. We expect to realize in excess of $20 million of synergies in the P&L in 2015.”

In the first quarter of 2015, Platform closed its acquisition of Arysta LifeScience Limited (“Arysta”). The Company also completed several financings related to this acquisition. These consisted of raising $2.1 billion in debt funding, including an aggregate of approximately $1.5 billion in U.S. dollar and Euro denominated bonds and approximately $750 million of new incremental credit facilities.

0/1200

More from AgroNewsChange

Hot Topic More

Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe AgroNews Daily Alert to send news related to your mailbox